The Food and Drug Administration Wednesday approved the expanded use of Rebetron, a treatment already on the market for hepatitis C, a viral infection of the liver that can lead to cirrhosis, liver cancer and liver failure.
The Food and Drug Administration on Wednesday approved a powerful combination of two antiviral drugs to treat chronic hepatitis C, a liver infection that can lead to cirrhosis, liver cancer and liver failure.
A standard AIDS drug appears to slow liver damage caused by hepatitis B. A study in Thursday's New England Journal of Medicine looked at the effects of the drug 3TC on people with long-standing infections with the virus.
One of the studies, led by Dr. John G. McHutchison of the Scripps Clinic and Research Foundation in La Jolla, California, compared the effects of the combination with interferon alone in the initial treatment of 912 patients.
In most developed countries, 1e to 2 percent of the population is infected with the virus, wrote Dr Adrian Di Bisceglie of Saint Louis University School of Medicine, in Missouri, the United States.
People infected with hepatitis C may have a better chance of a cure after researchers in Canada discovered a new combination of drugs to treat the disease.
In the Valley, the Arizona chapter of the Liver Foundation sponsors monthly support groups for patients, hosts seminars for patients and primary care physicians, and conducts programs in schools that alert children to the dangers of drug and alcohol abuse.
